Biotronik calls FDA's warning letter on stent "unfair"
This article was originally published in Clinica
Executive Summary
Biotronik is upset with the US FDA for choosing to issue a warning letter citing problems with how the company conducted its clinical trial for its Rithron-XR coronary stent.